CAMBRIDGE, Mass.--(BUSINESS WIRE)--ROME Therapeutics, a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for cancer and autoimmune diseases, today announced the appointment of Jeff Hatfield as Chair of the ROME Board of Directors. Currently serving as Chief Executive Officer of Vividion Therapeutics, Mr. Hatfield brings more than three decades of successful industry leadership across biotech and pharmaceuticals.

"We are excited to bring Jeff on to the ROME team as the Chair of our Board of Directors. His background across multiple therapeutic areas and his expertise in guiding novel platform companies to significant value will be of great benefit as we continue to grow and develop our pipeline," said Rosana Kapeller, M.D., Ph.D., President, Chief Executive Officer and Co-founder of ROME.

Mr. Hatfield leads development of a portfolio of first-in-class oncology and immunology programs at Vividion, which was acquired by Bayer Pharmaceuticals for $1.5 billion, and leverages a unique chemoproteomic discovery platform to target disease-causing proteins historically believed to be undruggable. Prior to joining Vividion, Mr. Hatfield served as Chief Executive Officer of Vitae Pharmaceuticals, a pioneer in computational structure-based drug discovery, where he oversaw the successful early development of several therapeutic programs and the company's ultimate acquisition by Allergan. Earlier in his career, he held multiple senior leadership roles at Bristol Myers Squibb, including Senior Vice President, Immunology and Virology Divisions, President, BMS-Canada and Head of U.S. Market Access.

More on Boston Chron

• Boom Boom Firearms Training LLC., Is Hosting Maryland Wear & Carry Permit (CCW) 16-Hour Courses For Eligible MD Residents & Non Residents
• Improvement, data science pros to convene in Atlanta Sept. 19-21
• Multi #1 International Best-Selling Author Jennifer S. Wilkov Announces the 2022 October Speak Up Women Conference and Last Call For Speakers
• Cellarity Releases Novel, Open-Source, Single-Cell Dataset and Invites the Machine Learning and Computational Biology Communities to Develop New Algorithms Capable of Learning Fundamental Rules of Cell Behavior
• Mandarina Houses presents a comprehensive solution to your real estate needs

"I am impressed by ROME's unique work to unlock the dark genome – the expansive portion of human DNA only now emerging as a valuable source of completely novel therapeutics in cancer and autoimmune diseases," said Mr. Hatfield. "This is an exciting time to join, with the science gaining momentum and multiple discovery programs underway. I look forward to working with the team to advance ROME's fascinating technologies and pipeline, with the clear goal of bringing new therapies to patients in need."

Mr. Hatfield currently serves on the Board of Directors of Vir Biotechnology and is a Key Advisory Board member for Harvard Business School's Blavatnik Fellowship in Life Science Entrepreneurship. He is also a faculty member at Purdue University, where he teaches entrepreneurship to doctoral students. Mr. Hatfield holds an MBA from The Wharton School of the University of Pennsylvania and a B.S. in pharmacy from Purdue University.

About ROME

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by illuminating the dark genome and decoding the repeatome within – the vast stretches of uncharted genetic material comprising repeat sequence motifs derived from the integration of viruses into the human genome throughout evolution. With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology. To lead this exploration, ROME has assembled a team of world-class leaders across oncology, immunology, virology and machine learning. ROME is based in Cambridge, Mass. For more information, please visit www.rometx.com.

More on Boston Chron

• Bundledocs launch new Cloud PDF Editor as part of their entry into North American market
• Inco-Check, LLC Becomes QC Ally, Unveiling a New Brand Identity that Reflects Company's Strategic Vision
• Non-profit Responds to Post Covid Needs
• Eagan Immigration Announces Their Debut on the Inc. 5000
• The Stage is Set for The 2022 DLH Inspire Awards in Hollywood

Contacts

Media
Lisa Qu
Ten Bridge Communications
lqu@tenbridgecommunications.com

Investor
Monique Allaire
THRUST Strategic Communications
monique@thrustsc.com

---

Show All News | Report Violation